Clinical evaluation of Rasayana compound as an adjuvant in the management of tuberculosis with anti-Koch's treatment
Journal name: AYU (Journal of Research in Ayurveda)
Original article title: Clinical evaluation of Rasayana compound as an adjuvant in the management of tuberculosis with anti-Koch's treatment
AYU is an internationally recognized quarterly journal dedicated to advancing research in Ayurveda. The journal covers a wide range of topics, including clinical and pharmacological research in Ayurveda's eight branches, herbal remedies, phytochemistry, and ethnomedicine.
Original source:
This page is merely a summary which is automatically generated hence you should visit the source to read the original article which includes the author, publication date, notes and references.
Purvi Vyas
H. M. Chandola
Firoz Ghanchi
Shivprakash Ranthem
AYU (Journal of Research in Ayurveda):
(An International Quarterly Journal of Research in Ayurveda)
Full text available for: Clinical evaluation of Rasayana compound as an adjuvant in the management of tuberculosis with anti-Koch's treatment
Year: 2012 | Doi: 10.4103/0974-8520.100307
Copyright (license): CC BY-NC-SA 4.0
Download the PDF file of the original publication
Summary of article contents:
Tuberculosis (TB) continues to intimidate the human race since time immemorial not only due to its effects as a medical malady, but also by its impact as a social and economic tragedy. At the dawn of the new millennium, we are still mute witnesses to the silent yet efficient march of this sagacious disease, its myriad manifestations and above all its unequalled, vicious power. Through the millennia, TB never ever disappeared from the developing world. In 1991, the World Health Assembly (WHA) resolution recognized TB as a major global public health problem. The DOTS strategy was launched in 1994, and became the global recommended strategy for TB control since then. The present study deals with clinical evaluation of Rasayana drugs considering of Amalaki (Emblica officinalis Gaertn.), Guduchi (Tinospora cordifolia willd.), Ashwagandha (Withania somnifera L.) Dunal, Yastimadhu (Glycyrrhiza glabra Linn.), Pippali (Piper longum Linn.), Sariva (Hemidesmus indicus R.Br.), Kustha (Saussurea lappa Falc.), Haridra (Curcuma longa Linn.) and Kulinjan (Alpinia galangal Linn.) as an adjuvant therapy with anti-Koch's treatment. The results obtained revealed that Rasayana compound was found to decrease cough (83%), fever (93%), dyspnea (71.3%), hemoptysis (87%) and increase body weight (7.7%) with statistically highly significant (P<0.001). Keywords: Anti-Koch's treatment, DOTS, Rasayana, tuberculosis
Other Science Concepts:
Discover the significance of concepts within the article: �Clinical evaluation of Rasayana compound as an adjuvant in the management of tuberculosis with anti-Koch's treatment�. Further sources in the context of Science might help you critically compare this page with similair documents:
Rasa, Agni, Rasayana therapy, Informed consent, Clinical evaluation, Statistically Significant, Adverse drug reaction, Socioeconomic factors, Global public health problem, Institutional ethics committee, Immunomodulatory effect, Body weight, Therapeutic regimen, Anti-Koch's treatment, DOTS strategy, Revised national tuberculosis control programme, Pulmonary TB, Tridoshaghna properties, Rasayana compound, Case detection rate, Decreased appetite, Serious Adverse Event.